{"id":353352,"date":"2010-02-23T11:40:10","date_gmt":"2010-02-23T16:40:10","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=64697"},"modified":"2010-02-23T11:40:10","modified_gmt":"2010-02-23T16:40:10","slug":"amylin-takeda-advance-obesity-drug","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/353352","title":{"rendered":"Amylin, Takeda Advance Obesity Drug"},"content":{"rendered":"\n
Biotech<\/a>, obesity<\/a>, Drugs<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN<\/a>), along with its partner<\/a> Takeda Pharmaceuticals, said<\/a> late Monday that their experimental combination of metreleptin and pramlintide<\/a> is being primed for final-stage Phase III clinical development for obesity. The decision was made after Amylin and Takeda reviewed data from a full 52 weeks of follow up from patients, which showed the drug consistently helped patients lose weight. Separately, Amylin said it is halting development of another obesity drug, davalintide, after a mid-stage trial showed it wasn’t as good as the combination therapy.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, obesity, Drugs Luke Timmerman wrote: San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN), along with its partner Takeda Pharmaceuticals, said late Monday that their experimental combination of metreleptin and pramlintide is being primed for final-stage Phase III clinical development for obesity. The decision was made after Amylin and Takeda reviewed data from a full 52 weeks […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-353352","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=353352"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353352\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=353352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=353352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=353352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}